Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Disease
Statistically Significant Improvement in Moderate-to-Severe Patients for Multiple Sign and Symptom Measures Phase 2/3 Clinical Trial Currently Planned for Mid-2021 Conference Call and Webcast Today at 8:00 a.m. ET Dec 15, 2020, 07:00 ET CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based …